Sagimet Biosciences (NASDAQ:SGMT) has received a "buy" rating from UBS Group with a price target of $12.00, indicating a potential upside of over 105%. Despite a "Moderate Buy" consensus rating, top analysts favor five other stocks over Sagimet. The company, focused on developing fatty acid synthase inhibitors, reported a quarterly EPS of ($0.25), surpassing estimates.